Array Biopharma Inc.

Intermune, Inc.

April L Kennedy

Steven Wade Andrews

Lawrence M Blatt

Yutong Jiang

Qian Zhao

James P Rizzi

George T Topalov

Timothy S Kercher

Mark C Munson

Scott D Seiwert

Martha E Rodriguez

Mark Laurence Boys

Robert Kirk DeLisle

Bryson Rast

Bin Wang

David A Mareska

Brad Newhouse

Erik James Hicken

Fredrik Pehr Marmsater

Michael Lyon

Robert J Kaus

Leonid Beigelman

Pierre Martin

Kevin Ronald Condroski

Weidong Liu

Paul Nichols

Robert Kirk Delisle

Andreas Schumacher

C Todd Eary

Tarek Sammakia

Bradley Barnett

Brad Owen Buckman

John A Josey

Peter J Stengel

Steven Mark Wenglowsky

D David Hennings

Fredrik P Marmsäter

Michael F Bradley

Matthew David Medina

Bradley R Barnett

Matthew Medina

Fredrik P Marmsater

Michael Bradley

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal. 

Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain. 

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Peptide inhibitors of hepatitis C virus replication

The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Inhibitors of hepatitis C virus replication

The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic compounds as inhibitors of viral replication

This invention relates to compounds comprising isocyano derivatives tethered to solid supports for use in 3 and 4 component condensation reactions. The invention also relates to methods for synthesizing cyclic derivatives by a 3 and 4 component condensation reaction using the compounds of the invention.

Isocyano substituted polystyrene carbonate resin for use in 3 and 4 component condensation reactions

Growing community of inventors

Denver, CO, United States of America

April L Kennedy